FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer ascopost.com
Regulatory Approvals
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer OncLive
FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults
FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults Pharmaceutical Executive
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s…
Globus Medical’s Excelsius3D imaging system receives CE mark
Globus Medical’s Excelsius3D imaging system receives CE mark Medical Device Network